United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

X	QUARTERLY REPORT PURSUANT TO SECT	TION 13 OR 15(d) OF T	HE SECURITIES	EXCHANGE ACT OF 1934			
	For	the Fiscal Quarter End	ed August 26, 200	7, or			
0	TRANSITION REPORT PURSUANT TO SECT	ΓΙΟΝ 13 OR 15(d) OF T	HE SECURITIES	EXCHANGE ACT OF 1934			
	For	the transition period fron	n to	.			
		Commission file nur	mber: 0-27446				
		LANDEC CORP	ORATION				
	(Exa	act name of registrant as		rter)			
	California			94-3025618			
	(State or other jurisdiction of incorporation or organization)			(IRS Employer Identification Number)			
		3603 Haven					
	(Addres	Menlo Park, Calif s of principal executive o		ip code)			
	Reg	istrant's telephone numbe (650) 306-		ode:			
during				tion 13 or 15(d) of the Securities Exchange Act of 1934 le such reports), and (2) has been subject to such filing			
		Yes x No	0 0				
	ate by check mark whether the registrant is a large ac accelerated filer" in Rule 12b-2 of the Exchange Ac		rated filer, or a nor	n-accelerated filer. See definition of "accelerated filer and			
Large	Accelerated Filer o Accel	lerated Filer x		Non Accelerated Filer o			
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).							
		Yes o	No x				
As of	September 14, 2007, there were 26,047,744 shares of	of Common Stock outsta	nding.				
			Ü				

LANDEC CORPORATION

FORM 10-Q For the Fiscal Quarter Ended August 26, 2007

INDEX

		Page
	Facing sheet	1
	Index	2
	index	_
Part I.	Financial Information	
Item 1.	Financial Statements	
	a) Consolidated Balance Sheets as of August 26, 2007 and May 27, 2007	3
	b) Consolidated Statements of Operations for the Three Months Ended August 26, 2007 and August 27, 2006	4
	c) Consolidated Statements of Cash Flows for the Three Months Ended August 26, 2007 and August 27, 2006	5
	d) Notes to Consolidated Financial Statements	6
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	29
Item 4	Controls and Procedures	29
Part II.	Other Information	30
Item 1.	Legal Proceedings	30
T. 4.8		
Item 1A.	Risk Factors	
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	30
Item 3.	Defaults Upon Senior Securities	30
Item 4.	Submission of Matters to a Vote of Security Holders	30
Item 5.	Other Information	30
Item 6.	Exhibits	30
itelli U.	LAMORS	30
	Signatures	31
	-2-	

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

LANDEC CORPORATION CONSOLIDATED BALANCE SHEETS (In thousands)

	A	August 26, 2007		May 27, 2007
	(U	naudited)	_	
ASSETS				
Current Assets:				
Cash and cash equivalents	\$	46,250	\$	62,556
Accounts receivable, less allowance for doubtful accounts of \$209 and \$206 at August 26, 2007 and May 27, 2007		17,643		17,631
Accounts receivable, related party		618		554
Inventories, net		7,800		6,800
Notes and advances receivable		147		282
Prepaid expenses and other current assets		1,558		1,316
Total Current Assets		74,016		89,139
Property and equipment, net		19,790		20,270
Goodwill, net		22,506		21,402
Trademarks, net		8,228		8,228
Notes receivable		96		96
Other assets		2,429		2,233
Total Assets	\$	127,065	\$	141,368
LIABILITIES AND SHAREHOLDERS' EQUITY				
Current Liabilities:				
Accounts payable	\$	16,259	\$	13,705
Related party accounts payable		466		175
Income taxes payable		482		458
Accrued compensation		1,224		3,126
Other accrued liabilities		1,626		1,340
Related party note payable		156		_
Deferred revenue		2,698		3,491
Total Current Liabilities		22,911	\$	22,295
Related party note payable		76		_
Deferred revenue		6,500		7,000
Minority interest		1,477		1,845
Total Liabilities		30,964		31,140
Shareholders' Equity:				
Common stock, \$0.001 par value; 50,000,000 shares authorized; 26,046,862 and 25,891,168 shares issued and outstanding at August 26, 2007 and May 27, 2007, respectively		130,455		129,560
Accumulated deficit		(34,354)		(19,332)
Total Shareholders' Equity		96,101		110,228
Total Liabilities and Shareholders' Equity	\$	127,065	\$	141,368

See accompanying notes.

LANDEC CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

(In thousands, except per share amounts)

	Three M	Three Months Ended		
	August 26,		August 27,	
D	2007		2006	
Revenues: Product sales	\$ 59,800) \$	50,046	
Services revenue, related party	1,075		843	
License fees	1,581		200	
Royalty revenues, related party	32		50	
Research, development and royalty revenues	171		8	
Total revenues	62,659		51,147	
Cost of revenue:				
Cost of product sales	51,592	,	43,288	
Cost of product sales, related party	1,212		1,549	
Cost of services revenue	881		754	
Total cost of revenue	53,685		45,591	
Gross profit	8,974	ļ	5,556	
Operating costs and expenses:				
Research and development	822		784	
Selling, general and administrative	4,546	,	4,902	
Total operating costs and expenses	5,368		5,686	
Operating income (loss)	3,606	,	(130)	
Interest income	781		236	
Interest expense	3)	6)	(70)	
Minority interest expense	(120)	(18)	
Other expense		_	(4)	
Net income before taxes	4,259		14	
Income tax expense	(1,182) _	<u> </u>	
Net income	\$ 3,077	\$	14	
Basic net income per share	\$ 0.12	\$	0.00	
Diluted net income per share (Note 4)	\$ 0.11	. \$	0.00	
Shares used in per share computation Basic	25,937	,	24,936	
Diluted		_		
Dituted	26,911	<u> </u>	24,936	

See accompanying notes.

LANDEC CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (In thousands)

August 26, 2007 August 27, 2006 Cash flows from operating activities: \$ 3,077 \$ 14 Adjustments to reconcile net income to net cash provided by (used in) operating activities: \$ 3,077 \$ 14 Adjustments to reconcile net income to net cash provided by (used in) operating activities: \$ 716 886 Income tax expense 1,132 — Stock-based compensation expense 325 246 Loss on sale of property and equipment — 4 Minority interest 120 78 Changes in current assets and current liabilities: (12) 2,483 Accounts receivable, net (12) 2,483 Accounts receivable, related party (64 664 Inventories, net (1,000) (2,039) Issuance of notes and advances receivable (2) — Collection of notes and advances receivable 141 168 Prepaid expenses and other current assets (242) (1,89) Accounts payable 2,554 (1,000)		Three mor	Three months Ended	
Cash flows from operating activities 8 3.07 8 10.00 Cash flows from operating activities 8 3.07 8 10.00 Attenuents to reconcile net income to net cash provided by (used in) operating activities: 75.00 88.00 Deprecation and amoritzation 7.13 8.00 Stoick-based compensation expense 1.32 2.40 Stoick-based compensation expense 1.00 7.00 Chosing sin current assets and current liabilities 1.01 2.40 Changes in current assets and current liabilities 1.01 2.40 Accounts receivable, net 1.00 (2.03) Accounts receivable, related pany 6.00 (2.03) Accounts receivable expenses and divence receivable 1.14 1.00 Inventories, net 1.10 (2.03) Issuance of notes and advances receivable 2.14 1.00 Accounts payable 2.53 1.00 Accounts payable 2.53 1.00 In cross taxes payable 2.1 1.0 In cross property and equipment 2.0 1.0 In cash provided by (seed o				_
Net incrome \$ 3,07 \$ \$ 14 Adjustments to reconcile net income to net cash provided by (used in) operating activities: 176 866 Depreciation and amorization 716 866 Income tax expense 1,132 — 46 866 Stock-based compensation expense 325 2-46 Loss on sale of property and equipment 120 78 Changes in current assets and current liabilities: 120 78 Changes in current assets and current liabilities: 464 (64 Accounts receivable, related party (64 (64 Inventories, net (100) (2,039) Issuance of notes and advances receivable (2) — Collection of notes and advances receivable (2) — Prepaid expenses and other current assets (242) (189 Accounts payable 291 (70 Related party accounts payable 291 (70 Accounts acces payable 291 (10 Accounted compensation (1,923) (151 Net cash provided by (used in) operating activities 291				
Net incrome \$ 3,07 \$ \$ 14 Adjustments to reconcile net income to net cash provided by (used in) operating activities: 176 866 Depreciation and amorization 716 866 Income tax expense 1,132 — 46 866 Stock-based compensation expense 325 2-46 Loss on sale of property and equipment 120 78 Changes in current assets and current liabilities: 120 78 Changes in current assets and current liabilities: 464 (64 Accounts receivable, related party (64 (64 Inventories, net (100) (2,039) Issuance of notes and advances receivable (2) — Collection of notes and advances receivable (2) — Prepaid expenses and other current assets (242) (189 Accounts payable 291 (70 Related party accounts payable 291 (70 Accounts acces payable 291 (10 Accounted compensation (1,923) (151 Net cash provided by (used in) operating activities 291	Cash flows from operating activities:			
Deperciation and annotization 716 886 Income tax expense 1,132 3.25 Stock-based compensation expense 3.25 2.26 Loss on sale of property and equipment 120 78 Changes in current assets and current liabilities: Accounts receivable, net 120 2,483 Accounts receivable, netded party 164 164 Inventories, net 1,1000 1,203 Issuance of notes and advances receivable 2(2		\$ 3,077	\$	14
Income tax expenses 1,132 — Stock-based compensation expense 2.46 Loss on sale of property and equipment — 4.4 Minority interest — 7.8 Changes in current assets and current liabilities: — 2.433 Accounts receivable, neated party (1.000) (2.039) Inventories, net (1.000) (2.039) Insuance of notes and advances receivable 141 168 Collection of notes and advances receivable 141 168 Prepaid expenses and other current assets (242) (189 Accounts payable 251 (7.00 Related party accounts payable 291 (70 Income taxes payable 291 (70 Accumed compensation (1,902) (2,020) Other accrued liabilities 291 10 Net cash provided by (used in) operating activities 291 (10 Net cash provided by (used in) operating activities 291 (1,235) Sasance of notes and advances receivable 2,342 2,342 Sas f	Adjustments to reconcile net income to net cash provided by (used in) operating activities:			
Stock-based compensation expense 325 246 Loss on sale of property and equipment - 4 Minority interest 120 78 Changes in current assets and current liabilities: - (12) 2.483 Accounts receivable, related party (64) (64) (64) Inventories, net (10) (2.039) 1.580 Issuance of notes and advances receivable (20) - Collection of notes and advances receivable (242) (189) Pepadid expenses and other current assets (242) (189) Accounts payable 2.54 (1,000) Related porty accounts payable 2.5 (1,000) Related porty accounts payable 2.4 - Accrued compensation (1,002) (2,302) Other accrued liabilities 2.91 1.0 Deferred revenue (1,23) (15) Net cash provided by (used in operating activities: 2.91 (20) Cash flows from investing activities: 2.02 (2.342) Issuance of notes and advances receivabl	Depreciation and amortization	716		886
Class on sale of property and equipment 120 78 78 78 78 78 78 78 7	Income tax expense	1,132		_
Minority interest 120 78 Changes in current assets and current liabilities: 4 2,483 Accounts receivable, related party (64) (64) (64) Inventories, net (100) (2,039) Issuance of notes and advances receivable (10) Collection of notes and advances receivable 141 168 Pepadie expenses and other current assets (242) (1899) Accounts payable 2,554 (1,000) Related party accounts payable 291 (70) Accrued compensation (1,902) (2,302) Other accrued liabilities 291 10 Deferred revenue (1,902) (2,302) Other accrued diabilities 291 10 Net cash provided by (used in) operating activities 291 10 Purchases of properly and equipment (2,32) 2,342 Essuance on totes and advances receivable (4) (15 Call (10) (2,342) 2,342 Essuance on totes and advances receivable (5) 3,23	Stock-based compensation expense	325		246
Changes in current assets and current liabilities: 12,843 Accounts receivable, related party (64) (64) Inventories, net (1,000) (2,039) I Inventories, net (1,000) (2,039) I Issuance of notes and advances receivable 141 168 Prepaid expenses and other current assets (242) (1,000) Accounts payable 2,554 (1,000) Accrued party accounts payable 291 (70) Income taxes payable 291 10 Other accrued liabilities 291 10 Offer accrued liabilities 291 10 Deferred revenue (1,293) (1,515) Net cash provided by (used in) operating activities 4,155 (1,295) Purchases of property and equipment 2,55 (2,342) Issuance of notes and advances receivable 4 (1 Collection of notes and advances receivable 2 3 Vectash flows from financing activities 2 3 Purchase of property and equipment 5 3 3	Loss on sale of property and equipment	_		4
Accounts receivable, net (12) 2.483 Accounts receivable party (6) (64) Inventories, net (1,000) (2,039) Issuance of notes and advances receivable (2) — Collection of notes and advances receivable 141 168 Prepaid expenses and other current assets (242) (189 Accounts payable 2,554 (1,000) Related party accounts payable 24 — Accrued compensation (1,002) (2,302) Other accrued liabilities (1,002) (2,302) Other accrued liabilities (1,002) (1,002) Other accrued liabilities (1,002) (1,002) Net cash provided by (used in) operating activities (1,002) (1,002) Cash flows from investing activities (2,342) (2,342) Issuance of notes and advances receivable (2,342) (2,342) Issuance of notes and advances receivable (2,342) (2,342) Cash flows from financing activities (2,342) (2,342) Proceeds from sale of common stock 5,70	Minority interest	120		78
Accounts receivable, related party (64) (64) Inventories, net (1,000) (2,038) Issuance of notes and advances receivable 141 168 Prepaid expenses and other current assets (242) (188) Accounts payable 2,554 (1,000) Related party accounts payable 291 (70) Income taxes payable 291 10 Accruel dompensation (1,902) (2,302) Other accrued liabilities 291 10 Deferred revenue (1,293) (151) Net cash provided by (used in) operating activities 291 (10 Susuance of notes and advances receivable (4) (155) Collection of notes and advances receivable (4) (154) Net cash provided by (used in) operating activities 20 14 Net cash used in investing activities 2(302) 2(342) Issuance of notes and advances receivable (4) (155) Collection of notes and advances receivable (5) 3(33) Repurchase of subsidiary options 5	Changes in current assets and current liabilities:			
Accounts receivable, related parry (64) (64) Inventories, net (1,000) (2,039) Issuance of notes and advances receivable (11 168 Collection of notes and advances receivable 141 168 Prepaid expenses and other current assets (242) (189) Accounts payable 2,554 (1,000) Related party accounts payable 291 (70) Income taxes payable 24 — Accrued compensation (1,902) (2,302) Other accrued liabilities 291 10 Deferred revenue (1,293) (151) Net cash provided by (used in) operating activities 291 (10,202) Cash flows from investing activities 4,156 (2,342) Issuance of notes and advances receivable (4) (155) Cash allows from investing activities 20 (2,342) Issuance of notes and advances receivable 50 373 Cash flows from financing activities 50 373 Proceeds from sale of common stock 50 373	-	(12)		2,483
Inventories, net (1,000) (2,039) Issuance of notes and advances receivable (2) — Collection of notes and advances receivable (14) 188 Prepatid expenses and other current assets (242) (189 Accounts payable 291 (70 Related party accounts payable 24 — Accrued compensation (1,902) (2,302) Other accrued liabilities 291 10 Deferred revenue (1,293) (151) Net cash provided by (used in) operating activities 291 (1,926) Cash flows from investing activities 291 (1,926) Cash flows from investing activities 2(20) (2,342) Esuance of notes and advances receivable (4) (2,342) Collection of notes and advances receivable (4) (2,342) Collection of notes and advances receivable (4) (2,342) Collection of notes and advances receivable (5) (3,33) Porceeds from sale of common stock (5) (3,33) Proceeds from sale of common stock (Accounts receivable, related party			(64)
Issuance of notes and advances receivable				(2,039)
Collection of notes and advances receivable 141 168 Prepaid expenses and other current assets 2.554 (1,000) Accounts payable 291 (70) Income taxes payable 291 (70) Income taxes payable 291 -7 Accrued compensation (1,902) (2,302) Other accrued liabilities 291 10 Deferred revenue (1,293) (151) Net cash provided by (used in) operating activities 4,156 (1,926) Purchases of property and equipment (236) (2,342) Purchases of notes and advances receivable (4) (15 Collection of notes and advances receivable (4) (15 Collection of notes and advances receivable (4) (15 Net cash used in investing activities 57 373 Proceeds from sale of common stock 57 373 Proceeds from sale of common stock 57 9 Proceeds from sale of common stock and options (Note 6) (20,596) - Repurchase of subsidiary common stock and options (Note 6) <td< td=""><td>Issuance of notes and advances receivable</td><td></td><td></td><td>_</td></td<>	Issuance of notes and advances receivable			_
Accounts payable 2,554 (1,000) Related party accounts payable 291 (700) Income taxes payable 24 — Accrued compensation (1,902) (2,302) Other accrued liabilities 291 10 Deferred revenue (1,293) (151) Net cash provided by (used in) operating activities 4,156 (1,926) Purchases of property and equipment (236) (2,342) Issuance of notes and advances receivable 4 (15) Collection of notes and advances receivable 4 (15) Cash flows from financing activities 240 (2,342) Cash used in investing activities 5 373 Proceeds from sale of common stock 5 373 Proceeds from the exercise of subsidiary options 5 9 Repurchase of subsidiary options 5 9 Repurchase of subsidiary options stock and options (Note 6) (20,596) 6 (Increase) decrease in other assets (196) 65 Issuance of related party note payable (Note 9) 232	Collection of notes and advances receivable			168
Accounts payable 2,554 (1,000) Related party accounts payable 291 (700) Income taxes payable 24 — Accrued compensation (1,902) (2,302) Other accrued liabilities 291 10 Deferred revenue (1,293) (151) Net cash provided by (used in) operating activities 4,156 (1,926) Purchases of property and equipment (236) (2,342) Issuance of notes and advances receivable 4 (15) Collection of notes and advances receivable 4 (15) Cash flows from financing activities 240 (2,342) Cash used in investing activities 5 373 Proceeds from sale of common stock 5 373 Proceeds from the exercise of subsidiary options 5 9 Repurchase of subsidiary options 5 9 Repurchase of subsidiary options stock and options (Note 6) (20,596) 6 (Increase) decrease in other assets (196) 65 Issuance of related party note payable (Note 9) 232	Prepaid expenses and other current assets	(242)		(189)
Related party accounts payable 291 (70) Income taxes payable 24 — Accrued compensation (1,902) (2,302) Other accrued liabilities 291 10 Deferred revenue (1,293) (151) Net cash provided by (used in) operating activities *** 1,293 Cash flows from investing activities: *** *** Purchases of property and equipment (36) (2,342) Issuance of notes and advances receivable (4) (15) Collection of notes and advances receivable (240) (2,342) Issuance of notes and advances receivable 57 373 Collection of notes and advances receivable (240) (2,342) Result cash used in investing activities: ** 9 Proceeds from financing activities ** 9 Repurchase of subsidiary options 57 373 Proceeds from the exercise of subsidiary options (196) 65 Increase) decrease in other assets (196) 65 Issuance of related party note payable (Note 9) <td< td=""><td></td><td></td><td></td><td></td></td<>				
Income taxes payable 24 — Accrued compensation (1,902) (2,302) Other accrued liabilities 291 10.0 Deferred revenue (1,293) (15.1) Net cash provided by (used in) operating activities 4,156 (1,926) Cash flows from investing activities: — 1 Purchases of property and equipment (236) (2,342) Issuance of notes and advances receivable (4) (15.7) Collection of notes and advances receivable (4) (15.7) Net cash used in investing activities 2 14 Net cash used in investing activities 570 373 Cash flows from financing activities 570 373 Proceeds from sale of common stock 570 373 Proceeds from sale of subsidiary options — 9 Repurchase of subsidiary common stock and options (Note 6) (20,596) — (Increase) decrease in other assets (196) 65 Issuance of related party note payable (Note 9) 232 — Payments to minority interest holders				(70)
Accrued compensation (1,902) (2,902) Other accrued liabilities 291 10 Deferred revenue (1,293) (151) Net cash provided by (used in) operating activities 4,156 (1,926) Cash flows from investing activities: **** **** Purchases of property and equipment (236) (2,342) Issuance of notes and advances receivable 4 (155) Ollection of notes and advances receivable - 14 Net cash used in investing activities: 2 4 Cash flows from financing activities 570 373 Proceeds from sale of common stock 570 373 Proceeds from sale of common stock and options (Note 6) (20,596) - Repurchase of subsidiary options - 9 Repurchase of subsidiary options (Note 6) (20,596) - (Increase) decrease in other assets (196) 65 Issuance of related party note payable (Note 9) 232 - Payments on long term debt (5) (1,973) Net cash used in financing activities		24		
Other accrued liabilities 291 10 Deferred revenue (1,293) (151) Net cash provided by (used in) operating activities 4,156 (1,926) Cash flows from investing activities: Very cash and advances receivable 2036 (2,342) Issuance of notes and advances receivable 41 (15 Collection of notes and advances receivable 41 (240) (2,343) Net cash used in investing activities: 373 373 Proceeds from financing activities: 570 373 Proceeds from the exercise of subsidiary options — 9 Repurchase of subsidiary common stock 570 373 Proceeds from the exercise of subsidiary options — 9 Repurchase of subsidiary common stock and options (Note 6) (20,596) — (Increase) decrease in other assets (196) 65 Issuance of related party note payable (Note 9) 323 — Payments to minority interest holders (227) (361) Payments to minority interest holders (227) (361) Net decrease in cash and cash eq		(1,902)		(2,302)
Deferred revenue (1,293) (151) Net cash provided by (used in) operating activities 4,156 (1,926) Cash flows from investing activities:	-			
Net cash provided by (used in) operating activities 4,156 (1,926) Cash flows from investing activities: 236 (2,342) Issuance of notes and advances receivable (4) (15) Collection of notes and advances receivable - 14 Net cash used in investing activities (240) (2,343) Cash flows from financing activities - 9 Cash flows from sale of common stock 570 373 Proceeds from sale of common stock 570 373 Proceeds from the exercise of subsidiary options - 9 Repurchase of subsidiary common stock and options (Note 6) (20,596) - (Increase) decrease in other assets (3) 6 Susuance of related party note payable (Note 9) 232 - Payments to minority interest holders (20,292) (1,873) Apyments to minority interest holders (20,222) (1,887) Net decrease in cash and cash equivalents (20,222) (1,887) Cash and cash equivalents at beginning of period (5,556) 20,519 Cash and cash equivalents at end of period	Deferred revenue			(151)
Cash flows from investing activities: (236) (2,342) Purchases of property and equipment (36) (2,342) Issuance of notes and advances receivable — 14 Collection of notes and advances receivable — 14 Net cash used in investing activities — 14 Cash flows from financing activities: — 9 Proceeds from sale of common stock — 9 Proceeds from the exercise of subsidiary options — 9 Repurchase of subsidiary common stock and options (Note 6) (20,596) — (Increase) decrease in other assets (196) 65 Issuance of related party note payable (Note 9) 232 — Payments on long term debt (5) (1,973) Payments to minority interest holders (20,222) (361) Net decrease in cash and cash equivalents (16,306) (6,156) Cash and cash equivalents at beginning of period 62,556 20,519 Cash and cash equivalents at end of period \$ 46,250 \$ 14,363 Supplemental schedule of noncash operating activities: \$ 1,132	Net cash provided by (used in) operating activities			
Purchases of property and equipment (236) (2,342) Issuance of notes and advances receivable (4) (15) Collection of notes and advances receivable - 14 Net cash used in investing activities (240) (2,343) Cash flows from financing activities: - - Proceeds from sale of common stock 570 373 Proceeds from the exercise of subsidiary options - 9 Repurchase of subsidiary common stock and options (Note 6) (20,596) - (Increase) decrease in other assets (196) 65 Issuance of related party note payable (Note 9) 232 - Payments to minority interest holders (20,20) (361) Net cash used in financing activities (227) (361) Net decrease in cash and cash equivalents (20,222) (1,887) Cash and cash equivalents at beginning of period 62,556 20,519 Cash and cash equivalents at end of period \$ 46,250 3 14,363 Supplemental schedule of noncash operating activities: \$ 1,132 \$ -				()
Purchases of property and equipment (236) (2,342) Issuance of notes and advances receivable (4) (15) Collection of notes and advances receivable - 14 Net cash used in investing activities (240) (2,343) Cash flows from financing activities: - - Proceeds from sale of common stock 570 373 Proceeds from the exercise of subsidiary options - 9 Repurchase of subsidiary common stock and options (Note 6) (20,596) - (Increase) decrease in other assets (196) 65 Issuance of related party note payable (Note 9) 232 - Payments to minority interest holders (20,20) (361) Net cash used in financing activities (227) (361) Net decrease in cash and cash equivalents (20,222) (1,887) Cash and cash equivalents at beginning of period 62,556 20,519 Cash and cash equivalents at end of period \$ 46,250 3 14,363 Supplemental schedule of noncash operating activities: \$ 1,132 \$ -	Cash flows from investing activities:			
Issuance of notes and advances receivable (4) (15) Collection of notes and advances receivable - 14 Net cash used in investing activities (240) (2,343) Cash flows from financing activities: - - Proceeds from sale of common stock 570 373 Proceeds from the exercise of subsidiary options - 9 Repurchase of subsidiary common stock and options (Note 6) (20,596) - (Increase) decrease in other assets (196) 65 Issuance of related party note payable (Note 9) 232 - Payments on long term debt (5) (1,973) Payments on inionity interest holders (227) (361) Net cash used in financing activities (227) (361) Net adecrease in cash and cash equivalents (16,306) (6,156) Cash and cash equivalents at beginning of period 62,556 20,519 Cash and cash equivalents at end of period \$ 46,250 \$ 14,363 Supplemental schedule of noncash operating activities: \$ 1,132 \$ -		(236)		(2.342)
Collection of notes and advances receivable — 14 Net cash used in investing activities (240) (2,343) Cash flows from financing activities: S70 373 Proceeds from sale of common stock 570 373 Proceeds from the exercise of subsidiary options — 9 Repurchase of subsidiary common stock and options (Note 6) (20,596) — (Increase) decrease in other assets (196) 65 (Increase) decrease in other assets (196) 65 Issuance of related party note payable (Note 9) 232 — Payments on long term debt (5) (1,973) Payments to minority interest holders (227) (361) Net cash used in financing activities (227) (362) Net decrease in cash and cash equivalents (16,306) (6,156) Cash and cash equivalents at beginning of period 62,556 20,519 Cash and cash equivalents at end of period \$ 46,250 14,363 Supplemental schedule of noncash operating activities: 1,132 — 1		` /		
Net cash used in investing activities (240) (2,343) Cash flows from financing activities: To cash flows from sale of common stock 570 373 Proceeds from the exercise of subsidiary options — 9 Repurchase of subsidiary common stock and options (Note 6) (20,596) — (Increase) decrease in other assets (196) 65 Issuance of related party note payable (Note 9) 232 — Payments on long term debt (5) (1,973) Payments to minority interest holders (20,222) (361) Net cash used in financing activities (20,222) (1,887) Net decrease in cash and cash equivalents (16,306) (6,156) Cash and cash equivalents at beginning of period 62,556 20,519 Cash and cash equivalents at end of period \$ 46,250 \$ 14,363 Supplemental schedule of noncash operating activities: \$ 1,132 \$ —				
Cash flows from financing activities: Proceeds from sale of common stock 570 373 Proceeds from the exercise of subsidiary options — 9 Repurchase of subsidiary common stock and options (Note 6) (20,596) — (Increase) decrease in other assets (196) 65 Issuance of related party note payable (Note 9) 232 — Payments on long term debt (5) (1,973) Payments to minority interest holders (227) (361) Net cash used in financing activities (20,222) (1,887) Net decrease in cash and cash equivalents (16,306) (6,156) Cash and cash equivalents at beginning of period 62,556 20,519 Cash and cash equivalents at end of period \$ 46,250 \$ 14,363 Supplemental schedule of noncash operating activities: \$ 1,132 \$ —	Net cash used in investing activities	(240)		
Proceeds from sale of common stock 570 373 Proceeds from the exercise of subsidiary options — 9 Repurchase of subsidiary common stock and options (Note 6) (20,596) — (Increase) decrease in other assets (196) 65 Issuance of related party note payable (Note 9) 232 — Payments on long term debt (5) (1,973) Payments to minority interest holders (227) (361) Net cash used in financing activities (20,222) (1,887) Net decrease in cash and cash equivalents (16,306) (6,156) Cash and cash equivalents at beginning of period 62,556 20,519 Cash and cash equivalents at end of period \$ 46,250 14,363 Supplemental schedule of noncash operating activities: \$ 1,132 \$ —		(2.13)		(2,5 15)
Proceeds from sale of common stock 570 373 Proceeds from the exercise of subsidiary options — 9 Repurchase of subsidiary common stock and options (Note 6) (20,596) — (Increase) decrease in other assets (196) 65 Issuance of related party note payable (Note 9) 232 — Payments on long term debt (5) (1,973) Payments to minority interest holders (227) (361) Net cash used in financing activities (20,222) (1,887) Net decrease in cash and cash equivalents (16,306) (6,156) Cash and cash equivalents at beginning of period 62,556 20,519 Cash and cash equivalents at end of period \$ 46,250 14,363 Supplemental schedule of noncash operating activities: \$ 1,132 \$ —	Cach flows from financing activities:			
Proceeds from the exercise of subsidiary options Repurchase of subsidiary common stock and options (Note 6) (Increase) decrease in other assets (I196) 65 Issuance of related party note payable (Note 9) Payments on long term debt (I5) (1,973) Payments to minority interest holders (I6,306) (6,156) Cash used in financing activities (I6,306) (6,156) Cash and cash equivalents at beginning of period (I6,306) (6,156) Cash and cash equivalents at end of period (I6,306) (1,306) Cash and cash equivalents at end of period (I6,306)		570		373
Repurchase of subsidiary common stock and options (Note 6) (20,596) — (Increase) decrease in other assets (196) 65 Issuance of related party note payable (Note 9) 232 — Payments on long term debt (5) (1,973) Payments to minority interest holders (227) (361) Net cash used in financing activities (20,222) (1,887) Net decrease in cash and cash equivalents (16,306) (6,156) Cash and cash equivalents at beginning of period (62,556) 20,519 Cash and cash equivalents at end of period (5,156) (1,973) Supplemental schedule of noncash operating activities: Income tax expense (1,32) —		370		
(Increase) decrease in other assets(196)65Issuance of related party note payable (Note 9)232—Payments on long term debt(5)(1,973)Payments to minority interest holders(227)(361)Net cash used in financing activities(20,222)(1,887)Net decrease in cash and cash equivalents(16,306)(6,156)Cash and cash equivalents at beginning of period62,55620,519Cash and cash equivalents at end of period\$ 46,250\$ 14,363Supplemental schedule of noncash operating activities:Income tax expense\$ 1,132\$ —		(20.596)		
Issuance of related party note payable (Note 9) Payments on long term debt Payments to minority interest holders Net cash used in financing activities (20,222) Net decrease in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental schedule of noncash operating activities: Income tax expense 232 — (1,973) (227) (361) (4,887) (1,887) (16,306) (6,156) (6,156) (20,222) (1,887) (20,222) (1,887) (20,222) (1,887) (20,306) (3,106) (4,306) (4,306) (5,106) (6,156) (6,156) (7,973) (1,				65
Payments on long term debt (1,973) Payments to minority interest holders (227) (361) Net cash used in financing activities (20,222) (1,887) Net decrease in cash and cash equivalents (16,306) (6,156) Cash and cash equivalents at beginning of period (52,556) (20,519) Cash and cash equivalents at end of period (54,250) (54,263) Supplemental schedule of noncash operating activities: Income tax expense (1,973) (361) Income tax expense (1,973) (3				
Payments to minority interest holders Net cash used in financing activities (20,222) (1,887) Net decrease in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental schedule of noncash operating activities: Income tax expense (16,306) (6,156) (20,222) (1,887) (16,306) (6,156) (20,525) (20,519) (361) (4,807) (5,156) (6,156) (6,156) (7,906) (1,807) (8,107) (9,107) (1,807) (1				(1 973)
Net cash used in financing activities (20,222) (1,887) Net decrease in cash and cash equivalents (16,306) (6,156) Cash and cash equivalents at beginning of period 62,556 20,519 Cash and cash equivalents at end of period \$46,250 \$14,363 Supplemental schedule of noncash operating activities: Income tax expense \$1,132 \$—				
Net decrease in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash and cash equivalents at end of period Supplemental schedule of noncash operating activities: Income tax expense (16,306) (6,156) 20,519 \$ 46,250 \$ 14,363				
Cash and cash equivalents at beginning of period 62,556 20,519 Cash and cash equivalents at end of period \$ 46,250 \$ 14,363 Supplemental schedule of noncash operating activities: Income tax expense \$ 1,132 \$ —	ivet cash used in inidicing activities	(20,222)	_	(1,887)
Cash and cash equivalents at beginning of period 62,556 20,519 Cash and cash equivalents at end of period \$ 46,250 \$ 14,363 Supplemental schedule of noncash operating activities: Income tax expense \$ 1,132 \$ —		(4.0.200)		(6.456)
Cash and cash equivalents at end of period \$ 46,250 \$ 14,363 Supplemental schedule of noncash operating activities: Income tax expense \$ 1,132 \$ —				
Supplemental schedule of noncash operating activities: Income tax expense \$ 1,132 \$ —			<u></u>	
Income tax expense <u>\$ 1,132</u> <u>\$ —</u>	-	\$ 46,250	\$	14,363
	Supplemental schedule of noncash operating activities:			
Preferred stock received from investment in unconsolidated business \$ — \$ 481	Income tax expense	\$ 1,132	\$	
	Preferred stock received from investment in unconsolidated business	\$ —	\$	481

See accompanying notes.

LANDEC CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

1. Basis of Presentation

Landec Corporation and its subsidiaries ("Landec" or the "Company") design, develop, manufacture, and sell temperature-activated and other specialty polymer products for a variety of food products, agricultural products, and licensed partner applications. The Company sells Intellicoat® coated seed products through its Landec Ag, Inc. ("Landec Ag") subsidiary and specialty packaged fresh-cut vegetables and whole produce to retailers and club stores, primarily in the United States and Asia through its Apio, Inc. ("Apio") subsidiary.

The accompanying unaudited consolidated financial statements of Landec have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions for Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring accruals) have been made which are necessary to present fairly the financial position at August 26, 2007 and the results of operations and cash flows for all periods presented. Although Landec believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in financial statements and related footnotes prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted per the rules and regulations of the Securities and Exchange Commission. The accompanying financial data should be reviewed in conjunction with the audited financial statements and accompanying notes included in Landec's Annual Report on Form 10-K for the fiscal year ended May 27, 2007.

The results of operations for the three months ended August 26, 2007 are not necessarily indicative of the results that may be expected for an entire fiscal year due to some seasonality in Apio's food business.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported results of operations during the reporting period. Actual results could differ materially from those estimates.

For instance, the carrying value of notes and advances receivable, are impacted by current market prices for the related crops, weather conditions and the fair value of the underlying security obtained by the Company, such as, liens on property and crops. The Company recognizes losses when it estimates that the fair value of the related crops or security is insufficient to cover the advance or note receivable.

Investments

Equity investments in non-public companies with no readily available market value are carried on the balance sheet at cost as adjusted for impairment losses, if any. If reductions in the market value of the investments to an amount that is below cost are deemed by management to be other than temporary, the reduction in market value will be realized, with the resulting loss in market value reflected on the income statement.

Recent Accounting Pronouncements

Fair Value Measurements

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities", including an Amendment of FASB Statement No. 115. SFAS No. 159 provides the option to measure, at fair value, eligible financial instrument items using fair value, which are not otherwise required to be measured at fair value. The irrevocable decision to measure items at fair value is made at specified election dates on an instrument-by-instrument basis. Changes in that instrument's fair value must be recognized in current earnings in subsequent reporting periods. If elected, the first measurement to fair value is reported as a cumulative-effect adjustment to the opening balance of retained earning in the year of adoption. The Company is currently evaluating the impact of the adoption of SFAS No. 159 on its consolidated financial statements, if it elects to measure eligible financial instruments at fair value. The standard is effective for the Company beginning in its fiscal year 2009.

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements" ("SFAS 157"). SFAS 157 defines fair value, establishes a framework for measuring fair value and expands disclosure of fair value measurements. SFAS 157 applies under other accounting pronouncements that require or permit fair value measurements and accordingly, does not require any new fair value measurements. SFAS 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007. The Company does not expect the adoption of SFAS 157 to have a material impact on its consolidated financial statements.

Reclassifications

Certain reclassifications have been made to prior period financial statements to conform to the current period presentation.

2. License Agreement with Monsanto Company

On December 1, 2006, Landec sold its direct marketing and sales seed company, Fielder's Choice Direct ("FCD"), which included the Fielder's Choice Direct and Heartland Hybrid brands, to American Seeds, Inc., a wholly owned subsidiary of Monsanto Company ("Monsanto"). The acquisition price for FCD was \$50 million in cash paid at the close. During fiscal year 2007, Landec recorded income from the sale, net of direct expenses and bonuses, of \$22.7 million. The income that was recorded is equal to the difference between the fair value of FCD of \$40 million and its net book value, less direct selling expenses and bonuses. In accordance with generally accepted accounting principles, the portion of the \$50 million of proceeds in excess of the fair value of FCD, or \$10 million, will be allocated to the technology license agreement described below and will be recognized as revenue ratably over the five year term of the technology license agreement or \$2 million per year beginning December 1, 2006. The fair value was determined by management with the assistance of an independent appraiser.

On December 1, 2006, Landec also entered into a five-year co-exclusive technology license and polymer supply agreement (the "Agreement") with Monsanto for the use of Landec's Intellicoat polymer seed coating technology. Under the terms of the Agreement, Monsanto will pay Landec \$2.6 million per year in exchange for (1) a co-exclusive right to use Landec's Intellicoat temperature activated seed coating technology worldwide during the license period, (2) the right to be the exclusive global sales and marketing agent for the Intellicoat seed coating technology, and (3) the right to purchase the technology any time during the five year term of the Agreement. Monsanto will also fund all operating costs, including all Intellicoat research and development, product development and non-replacement capital costs during the five year agreement period. For the three months ended August 26, 2007, Landec recognized \$1.35 million in revenues and income from the Agreement.

The Agreement also provides for a fee payable to Landec of \$4 million if Monsanto elects to terminate the Agreement or \$8 million if Monsanto elects to purchase the technology. If the purchase option is exercised before the fifth anniversary of the Agreement, or if Monsanto elects to terminate the Agreement, all annual license fees and supply payments that have not been paid to Landec will become due upon the purchase. If Monsanto does not exercise its purchase option by the fifth anniversary of the Agreement, Landec will receive the termination fee and all rights to the Intellicoat seed coating technology will revert to Landec. Accordingly, Landec will receive minimum guaranteed payments of \$17 million, or \$3.4 million per year, for license fees and polymer supply payments over five years or \$21 million in maximum payments if Monsanto elects to purchase the licensed technology. If Monsanto elects to purchase the technology, an additional \$4 million of license fee revenue will be recognized at the time of purchase. If Monsanto exercises its purchase option, Landec and Monsanto will enter into a new long-term supply agreement in which Landec will continue to be the exclusive supplier of Intellicoat polymer materials to Monsanto.

Landec Ag revenues and operating losses for the three months ended August 27, 2006, prior to the sale of FCD, were \$114,000 and \$2.5 million or \$0.10 per diluted share, respectively.

3. Stock-Based Compensation

On May 29, 2006, the Company adopted SFAS 123R, which is a revision of SFAS No. 123 "Accounting for Stock-Based Compensation" ("SFAS 123"), and supersedes APB No. 25, "Accounting for Stock Issued to Employees" ("APB 25"). Among other items, SFAS 123R requires companies to record compensation expense for stock-based awards issued to employees and directors in exchange for services provided. The amount of the compensation expense is based on the estimated fair value of the awards on their grant dates and is recognized over the required service periods. The Company's stock-based awards include stock option grants and restricted stock unit awards (RSUs).

Prior to the adoption of SFAS 123R, the Company applied the intrinsic value method set forth in APB 25 to calculate the compensation expense for stock-based awards. The Company has historically set the exercise price for its stock options equal to the market value on the grant date. As a result, the options had no intrinsic value on their grant dates, and therefore the Company did not record any compensation expense unless the terms of the stock options were subsequently modified. For RSUs, the calculation of compensation expense under APB 25 and SFAS 123R is similar except for the accounting treatment for forfeitures as discussed below.

The Company adopted SFAS 123R using the modified prospective transition method, which requires the application of the accounting standard to (i) all stock-based awards issued on or after May 29, 2006 and (ii) any outstanding stock-based awards that were issued but not vested as of May 29, 2006. In the three months ended August 26, 2007, the Company recognized stock-based compensation expense of \$324,668 or \$0.01 per basic and diluted share, which included \$62,964 for restricted stock unit awards and \$261,704 for stock option grants.

The following table summarizes the stock-based compensation by income statement line item:

	I	e Months Ended st 26, 2007	Three Months Ended August 27, 200		
Research and development	\$	31,583	\$	19,070	
Sales, general and administrative	\$	293,085	\$	226,842	
Total stock-based compensation	\$	324,668	\$	245,912	

The estimated fair value for stock options, which determines the Company's calculation of compensation expense, is based on the Black-Scholes pricing model. Upon the adoption of SFAS 123R, the Company changed its method of calculating and recognizing the fair value of stock-based compensation arrangements to the straight-line, single-option method. Compensation expense for all stock option grants and restricted stock awards granted prior to May 29, 2006, will continue to be recognized using the straight-line, multiple-option method. In addition, SFAS 123R requires the estimation of expected forfeitures of stock-based awards at the time of grant. As a result, the Company uses historical data to estimate pre-vesting forfeitures and records stock-based compensation expense only for those awards that are expected to vest and revises those estimates in subsequent periods if the actual forfeitures differ from prior estimates.

Valuation Assumptions

As of August 26, 2007 and August 27, 2006, the fair value of stock option grants was estimated using the Black-Scholes option pricing model. The following weighted average assumptions were used:

	Three Month	s Ended
	August 26, 2007	August 27, 2006
Stock option plan:		_
Risk-free interest rate	5.02%	5.08%
Dividend yield	0%	0%
Volatility	46%	51%
Expected term in years	4.40	4.27

Stock-Based Compensation Activity

	Restrict	ted Stock Outsta	Stock Options	s Outstanding	
	RSUs and		Weighted		
	Options	Number of	Average		Weighted
	Available	Restricted	Grant Date	Number of	Average
	for Grant	Shares	Fair Value	Stock Options	Exercise Price
Balance at May 27, 2007	706,731	38,335	\$ 8.86	2,061,337	\$ 5.14
Granted	(139,335)	34,835	\$ 13.32	104,500	\$ 13.32
Awarded/Exercised	_	(10,002)	\$ 8.86	(145,692)	\$ 3.90
Forfeited	<u> </u>	<u> </u>	\$ —		\$ —
Balance at August 26, 2007	567,396	.63,168	\$ 11.32	2,020,145	\$ 5.66

The following table summarizes information concerning stock options outstanding and exercisable at August 26, 2007:

	Options Outstanding			Options Exercisable			
Range of Exercise Prices	Number of Shares Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price	Aggregate Intrinsic Value	Number of Shares Exercisable	Weighted Average Exercise Price	Aggregate Intrinsic Value
		(in years)					
\$ 1.660 - \$3.250	244,363	4.87	\$ 2.91	\$ 2,683,106	244,363	\$ 2.91	\$ 2,683,106
\$ 3.375 - \$3.375	258,247	3.28	\$ 3.38	\$ 2,714,176	258,247	\$ 3.38	\$ 2,714,176
\$ 3.400 - \$3.700	206,146	2.95	\$ 3.47	\$ 2,148,041	206,146	\$ 3.47	\$ 2,148,041
\$ 3.375 - \$6.125	303,617	2.75	\$ 5.02	\$ 2,693,083	298,617	\$ 5.01	\$ 2,651,719
\$ 6.130 - \$6.130	262,000	4.73	\$ 6.13	\$ 2,033,120	196,375	\$ 6.13	\$ 1,523,870
\$ 6.450 - \$6.750	338,300	4.25	\$ 6.68	\$ 2,439,143	338,300	\$ 6.68	\$ 2,439,143
\$ 6.790 - \$8.860	302,972	6.67	\$ 7.75	\$ 1,860,248	251,020	\$ 7.52	\$ 1,598,997
\$ 13.32 - \$13.32	104,500	6.84	\$ 13.32	\$ 59,565	30,968	\$ 13.32	\$ 17,652
\$ 1.660 - \$13.32	2,020,145	4.40	\$ 5.66	\$16,630,482	1,824,036	\$ 5.24	\$ 15,776,704

The aggregate intrinsic value in the table above represents the total pretax intrinsic value, based on the Company's closing stock price of \$13.89 on August 24, 2007, which would have been received by holders of stock options had all holders of stock options exercised their stock options that were in-themoney as of that date. The total number of in-the-money stock options exercisable as of August 26, 2007, was approximately 1.8 million shares. The aggregate intrinsic value of stock options exercised during the three month period ended August 26, 2007, was \$1.0 million.

Shares Subject to Vesting

The following table summarizes the activity relating to unvested stock option grants and RSUs during the three month period ended August 26, 2007:

	Stock Options			Restrict	Stock	
	Shares	A	Weighted Average Fair Value	Shares		Weighted Average Fair Value
Unvested at May 27, 2007	140,913	\$	3.70	38,335	\$	8.32
Granted	104,500	\$	5.57	34,835	\$	12.49
Vested/Awarded	(49,304)	\$	5.31	(10,002)	\$	6.30
Forfeited	_	\$	_	_	\$	_
Unvested at August 26, 2007	196,109	\$	4.29	63,168	\$	8.57

As of August 26, 2007, there was \$1.4 million of total unrecognized compensation expense related to unvested equity compensation awards granted under the Company's incentive stock plan. Total expense is expected to be recognized over the weighted-average period of 1.63 years.

As of August 26, 2007 the Company has reserved 2.7 million shares of common stock for future issuance under its current and former stock plans.

4. Income Taxes

The estimated annual effective tax rate for fiscal 2008 is expected to be approximately 28%. The primary difference between the estimated annual effective tax rate of 28% and the federal statutory tax rate relates to the projected utilization of net operating loss and credit carryforwards. The provision for income taxes for the three months ended August 26, 2007 was approximately \$1.2 million.

In June 2006, the Financial Accounting Standards Board (FASB) issued Interpretation No. 48, "Accounting for Uncertainty in Income Taxes" ("FIN 48"). FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements in accordance with Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes" ("FAS 109"). This interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN 48 also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure, and transition.

The Company adopted FIN 48 effective May 28, 2007. As a result of the implementation of FIN 48, the Company did not recognize a cumulative adjustment to the May 28, 2007 balance of retained earnings as the amount was deemed immaterial.

As of May 28, 2007, the Company had unrecognized tax benefits of approximately \$277,000. Included in the balance of unrecognized tax benefits as of May 28, 2007 is approximately \$259,000 of tax benefits that, if recognized, would result in an adjustment to the Company's effective tax rate.

In accordance with FIN 48, paragraph 19, the Company has decided to classify interest and penalties related to uncertain tax positions as a component of its provision for income taxes. Due to the Company's historical taxable loss position, the Company did not accrue interest and penalties relating to the income tax on the unrecognized tax benefits as of May 27, 2007 and August 26, 2007 as the amounts were immaterial. Accordingly, the amount of interest and penalties included as a component of provision for income taxes in the quarter ended August 26, 2007 is immaterial.

Due to tax attribute carryforwards, the Company is subject to examination for tax years 1991 forward for U.S. tax purposes. The Company was also subject to examination in various state jurisdictions for tax years 1996 forward, none of which were individually material. The Company does not expect that the amounts of unrecognized tax benefits will change significantly within the next twelve months.

5. Net Income Per Diluted Share

The following table sets forth the computation of diluted net income for the periods with net income (in thousands, except per share amounts):

		Ended		Ended Ended		Ended
Numerator:						
Net income	\$	3,077	\$	14		
Less: Minority interest income of subsidiary		(89)		(114)		
Net income (loss) for diluted net income (loss) per share	\$	2,988	\$	(100)		
Denominator:						
Weighted average shares for basic net income per share		25,937		24,936		
Effect of dilutive securities:						
Stock Options		974		_		
Weighted average shares for diluted net income per share		26,911		24,936		
Diluted net income per share	\$	0.11	\$	(0.00)		

For the three months ended August 26, 2007 and August 27, 2006, the computation of the diluted net income (loss) per share excludes the impact of options to purchase 68,901 shares and 1,367,667 shares of Common Stock, respectively, as such impacts would be antidilutive for these periods.

6. Repurchase of Subsidiary Common Stock and Options

On August 7, 2007, Landec repurchased all of the outstanding common stock and options of Apio not owned by Landec at the fair market value of each share as if all options had been exercised on that date. The fair market value repurchase price for all of Apio's common stock and options not owned by Landec was \$20.6 million. After the repurchase, Apio became a wholly owned subsidiary of Landec. In accordance with SFAS 123R, this repurchase did not result in additional compensation expense to the Company as all of the common stock and options repurchased were fully vested at the time of the repurchase and the consideration paid was equal to the fair value on the date of the repurchase. The repurchase of Apio's outstanding common stock for \$1.1 million was recorded to goodwill. The repurchase of Apio's options for \$19.5 million was recorded as a reduction to retained earnings. In addition, the repurchase resulted in a tax deduction of \$19.7 million during the first quarter of fiscal year 2008.

7. Goodwill and Other Intangibles

The Company is required under SFAS 142 to review goodwill and indefinite lived intangible assets at least annually. During the three months ended August 26, 2007, the Company completed its annual impairment review. The review is performed by grouping the net book value of all long-lived assets for reporting entities, including goodwill and other intangible assets, and comparing this value to the related estimated fair value. The determination of fair value is based on estimated future discounted cash flows related to these long-lived assets. The discount rate used was based on the risks associated with the reporting entities. The determination of fair value was performed by management. The review concluded that the fair value of the reporting entities exceeded the carrying value of their net assets and thus no impairment charge was warranted as of August 26, 2007. As a result of the repurchase of Apio's outstanding common stock (see Note 6), goodwill increased \$1.1 million during the first quarter of fiscal year 2008.

8. Inventories

Inventories are stated at the lower of cost (first-in, first-out method) or market and consisted of the following (in thousands):

	gust 26, 2007	May 27, 2007		
Finished goods	\$ 4,012	\$	2,273	
Raw material	3,788		4,527	
Total	\$ 7,800	\$	6.800	

9. Related Party

Apio provides cooling and distributing services for farms in which the Chief Executive Officer of Apio (the "Apio CEO") has a financial interest and purchases produce from those farms. Apio also purchases produce from Beachside Produce LLC for sale to third parties. Beachside Produce is owned by a group of entities and persons that supply produce to Apio. One of the owners of Beachside Produce is the Apio CEO. Revenues, cost of product sales and the resulting payable and the note receivable from advances for ground lease payments, and crop and harvesting costs, are classified as related party in the accompanying financial statements as of August 26, 2007 and May 27, 2007 and for the three months ended August 26, 2007 and August 27, 2006.

Apio leases, for approximately \$289,000 on an annual basis, agricultural land that is either owned, controlled or leased by the Apio CEO. Apio, in turn, subleases that land at cost to growers who are obligated to deliver product from that land to Apio for value added products. There is generally no net statement of operations impact to Apio as a result of these leasing activities but Apio creates a guaranteed source of supply for the value added business. Apio has loss exposure on the leasing activity to the extent that it is unable to sublease the land. For the three months ended August 26, 2007, the Company subleased all of the land leased from the Apio CEO and received sublease income of \$112,000 which is equal to the amount the Company paid to lease that land for the period.

Apio's domestic commodity vegetable business was sold to Beachside Produce, effective June 30, 2003. The Apio CEO is a 12.5% owner in Beachside Produce. During the three months ended August 26, 2007, the Company recognized revenues of \$371,000 from the sale of products to Beachside Produce and royalty revenue of \$32,000 from the use by Beachside Produce of Apio's trademarks. The related accounts receivable from Beachside Produce are classified as related party in the accompanying financial statements as of August 26, 2007 and May 27, 2007.

At May 27, 2007, the Apio CEO held a 6% ownership interest in Apio Cooling LP ("Apio Cooling"), a limited partnership in which Apio is the general partner and majority owner with a 60% ownership interest. During the first quarter of fiscal year 2008, the Apio CEO withdrew from Apio Cooling. In accordance with the partnership agreement, the Apio CEO's minority interest will be paid in three annual installments with the first payment made in the second quarter of fiscal year 2008. The amounts due are classified as a related party note payable as of August 26, 2007 in the accompanying financial statements. As of May 27, 2007, the \$227,000 owed to the Apio CEO was included in the minority interest liability as the Apio CEO did not withdraw from Apio Cooling until the first quarter of fiscal year 2008.

All related party transactions are monitored quarterly by the Company and approved by the Audit Committee of the Board of Directors.

10. Comprehensive Loss

The comprehensive income of Landec is the same as net income.

11. Shareholders' Equity

During the three months ended August 26, 2007, 155,694 shares of Common Stock were issued upon the vesting of RSUs and upon the exercise of options under the Company's stock option plans.

12. Business Segment Reporting

Landec operates in two business segments: the Food Products Technology segment and the Technology Licensing segment. The Food Products Technology segment markets and packs specialty packaged whole and fresh-cut vegetables that incorporate the BreatheWay® specialty packaging for the retail grocery, club store and food services industry. In addition, the Food Products Technology segment sells BreatheWay packaging to partners for non-vegetable products. The Technology Licensing segment consists of licensing agreements for seed coatings using Landec's patented Intellicoat seed coatings to the farming industry and for the use of the Company's Intelimer® polymers for personal care products and other industrial products. Corporate includes corporate general and administrative expenses, non Food Products Technology interest income and Company-wide income tax expenses. All of the assets of the Company are located within the United States of America. Prior to fiscal year 2008, Landec's operating segments were Food Products Technology, which has not changed, and Agricultural Seed Technology. As a result of the sale of FCD to Monsanto (see Note 2), the Company has eliminated the Agricultural Seed Technology segment and has established the Technology Licensing segment. As a result, the segment information for the first quarter of fiscal year 2007 has been reclassified to conform with the current year classification. Included in the Technology Licensing segment for the first quarter of fiscal year 2007 are the results of Landec Ag which includes FCD. In addition, the licensing activity for non food and Ag collaborations is included in the Technology Licensing segment whereas in periods prior to fiscal year 2008 it was included in the Corporate.

Operations by Business Segment (in thousands):

Three months ended August 26, 2007	Food Products Technology		Technology Licensing		Corporate		TOTAL	
Net revenues	\$	60,998	\$ 1,661	\$		\$	62,659	
International sales	\$	19,250	\$ 3⁄4	\$	3/4	\$	19,250	
Gross profit	\$	7,313	\$ 1,661	\$	_	\$	8,974	
Net income (loss)	\$	3,676	\$ 1,209	\$	(1,808)	\$	3,077	
Interest expense	\$	8	\$ 3/4	\$	3/4	\$	8	
Interest income	\$	223	\$ _	\$	558	\$	781	
Depreciation and amortization	\$	659	\$ 57	\$	_	\$	716	
Income tax expense	\$	_	\$ _	\$	1,182	\$	1,182	
Three months ended August 27, 2006								
Net revenues	\$	50,825	\$ 322	\$	_	\$	51,147	
International sales	\$	13,810	\$ 3⁄4	\$	3/4	\$	13,810	
Gross profit	\$	5,354	\$ 202	\$	_	\$	5,556	
Net income (loss)	\$	2,426	\$ (2,667)	\$	255	\$	14	
Interest expense	\$	70	\$ 3/4	\$	3/4	\$	70	
Interest income	\$	192	\$ _	\$	44	\$	236	
Depreciation and amortization	\$	672	\$ 214	\$	_	\$	886	
Income tax expense	\$	_	\$ 3⁄4	\$	3/4	\$	_	

During the three months ended August 26, 2007 and August 27, 2006, sales to the Company's top five customers accounted for 49% and 51%, respectively, of revenues with the Company's top customer from the Food Products Technology segment, Costco Wholesale Corp., accounting for 20% for the three months ended August 26, 2007 and 21% for the three months ended August 27, 2006. The Company expects that, for the foreseeable future, a limited number of customers may continue to account for a significant portion of its net revenues. Virtually all of the Company's international sales are to Asia.

13. Subsequent Events

On September 24, 2007, the Company amended its licensing and supply agreement with Chiquita Brands International, Inc. ("Chiquita"). Under the terms of the amendment, the license for bananas has been expanded to include additional exclusive fields using Landec's BreatheWay packaging technology and, a new exclusive license has been added for the sale and marketing of avocados using Landec's BreatheWay packaging technology. In exchange for expanding the exclusive fields for bananas and adding a new exclusive field for avocados, the minimum gross profits to be received by Landec from the sale of BreatheWay packaging to Chiquita for bananas and avocados will increase to \$2.9 million in fiscal year 2008 and to \$2.2 million in fiscal year 2009. In addition, the minimum gross profits to be received will be divided evenly over each calendar quarter and thus will be due at the end of March, June, September and December of each year.

On September 1, 2007, Apio amended its revolving line of credit with Wells Fargo Bank N.A. extending the term of the line to August 31, 2009. In addition, the interest rate on the revolving line of credit was reduced from either prime less 0.50% or the LIBOR adjusted rate plus 1.50%. The revolving line of credit with Wells Fargo contains certain restrictive covenants, which require Apio to meet certain financial tests, including minimum levels of net income, maximum leverage ratio, minimum net worth and maximum capital expenditures. Landec has pledged substantially all of the assets of Apio to secure the line of credit with Wells Fargo. At August 26, 2007, no amounts were outstanding under the revolving line of credit. Apio has been in compliance or obtained waivers for all loan covenants since the inception of this loan.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the unaudited consolidated financial statements and accompanying notes included in Part I--Item 1 of this Form 10-Q and the audited consolidated financial statements and accompanying notes and Management's Discussion and Analysis of Financial Condition and Results of Operations included in Landec's Annual Report on Form 10-K for the fiscal year ended May 27, 2007.

Except for the historical information contained herein, the matters discussed in this report are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Potential risks and uncertainties include, without limitation, those mentioned in this report and, in particular the factors described below under "Additional Factors That May Affect Future Results," and those mentioned in Landec's Annual Report on Form 10-K for the fiscal year ended May 27, 2007. Landec undertakes no obligation to update or revise any forward-looking statements in order to reflect events or circumstances that may arise after the date of this report.

Critical Accounting Policies and Use of Estimates

There have been no material changes to the Company's critical accounting policies which are included and described in the Form 10-K for the fiscal year ended May 27, 2007 filed with the Securities and Exchange Commission on July 27, 2007.

The Company

Landec Corporation and its subsidiaries ("Landec" or the "Company") design, develop, manufacture and sell temperature-activated and other specialty polymer products for a variety of food products, agricultural products, and licensed partner applications. This proprietary polymer technology is the foundation, and a key differentiating advantage, upon which Landec has built its business.

Landec's core polymer products are based on its patented proprietary Intelimer polymers, which differ from other polymers in that they can be customized to abruptly change their physical characteristics when heated or cooled through a pre-set temperature switch. For instance, Intelimer polymers can change within the range of one or two degrees Celsius from a non-adhesive state to a highly tacky, adhesive state; from an impermeable state to a highly permeable state; or from a solid state to a viscous state. These abrupt changes are repeatedly reversible and can be tailored by Landec to occur at specific temperatures, thereby offering substantial competitive advantages in Landec's target markets.

Subsequent to the sale of Landec's former direct marketing and sales seed corn company, Fielder's Choice Direct ("FCD"), to Monsanto in fiscal year 2007, Landec now has two core businesses – Food Products Technology and Technology Licensing (see note 12).


Our Food Products Technology business is operated through a subsidiary, Apio, Inc., and combines our proprietary food packaging technology with the capabilities of a large national food supplier and value-added produce processor. Value-added processing incorporates Landec's proprietary packaging technology with produce that is processed by washing, and in some cases cutting and mixing, resulting in packaged produce to achieve increased shelf life and reduced shrink (waste) and to eliminate the need for ice during the distribution cycle. This combination was consummated in 1999 when the Company acquired Apio, Inc. and certain related entities (collectively, "Apio").

Our Technology Licensing business includes our proprietary Intellicoat seed coating technology which we have licensed to Monsanto and our Intelimer polymer business that licenses and/or supplies products outside of our Food Products Technology business to companies such as Air Products and Chemicals, Inc. ("Air Products") and Nitta Corporation ("Nitta").

Landec was incorporated in California on October 31, 1986. We completed our initial public offering in 1996 and our Common Stock is listed on The NASDAQ Global Select Market under the symbol "LNDC." Our principal executive offices are located at 3603 Haven Avenue, Menlo Park, California 94025 and our telephone number is (650) 306-1650.

Description of Core Business

Landec participates in two core business segments- Food Products Technology and Technology Licensing.



Food Products Technology Business

The Company began marketing in early 1996 our proprietary Intelimer-based specialty packaging for use in the fresh-cut produce market, one of the fastest growing segments in the produce industry. Our proprietary BreatheWay packaging technology, when combined with produce that is processed by washing, and in some cases cut and mixed, results in packaged produce with increased shelf life, reduced shrink (waste) and without the need for ice during the distribution cycle, which we refer to as our "value-added" products. In 1999, we acquired Apio, our largest customer at that time in the Food Products Technology business and one of the nation's leading marketers and packers of produce and specialty packaged fresh-cut vegetables. Apio provides year-round access to produce, utilizes state-of-the-art fresh-cut produce processing technology and distributes products to the top U.S. retail grocery chains, major club stores and to the foodservice industry. The vertical integration of Landec's BreatheWay technology and Apio's packaging and sales capabilities within the Food Products Technology business gives Landec direct access to the large and growing fresh-cut produce market. The value-added business markets a variety of fresh-cut and whole vegetables to the top retail grocery chains and club stores. During the fiscal year ended May 27, 2007, Apio shipped more than seventeen million cartons of produce to leading supermarket retailers, wholesalers, foodservice suppliers and club stores throughout the United States and internationally, primarily in Asia.

There are five major distinguishing characteristics of Apio that provide competitive advantages in the Food Products Technology market:

- **Value-Added Supplier:** Apio has structured its business as a marketer and seller of fresh-cut and whole value-added produce. It is focused on selling products under its Eat Smart® brand and other brands for its fresh-cut and whole value-added products. As retail grocery and club store chains consolidate, Apio is well positioned as a single source of a broad range of products.
- **Reduced Farming Risks:** Apio reduces its farming risk by not taking ownership of farmland, and instead, contracts with growers for produce. The year-round sourcing of produce is a key component to the fresh-cut and whole value-added processing business.
- Lower Cost Structure: Apio has strategically invested in the rapidly growing fresh-cut and whole value-added business. Apio's 96,000 square foot value-added processing plant, which was expanded in fiscal year 2007 from 60,000 square feet, is automated with state-of-the-art vegetable processing equipment. Virtually all of Apio's value-added products utilize Apio's proprietary BreatheWay packaging technology. Apio's strategy is to operate one large central processing facility in one of California's largest, lowest cost growing regions (Santa Maria Valley) and use packaging technology to allow for the nationwide delivery of fresh produce products.
- **Export Capability:** Apio is uniquely positioned to benefit from the growth in export sales to Asia and Europe over the next decade with its export business, CalEx. Through CalEx, Apio is currently one of the largest U.S. exporters of broccoli to Asia and is selling its iceless products to Asia using proprietary BreatheWay packaging technology.
- **Expanded Product Line Using Technology:** Apio, through the use of its BreatheWay packaging technology, is introducing on average fifteen new value-added products each year. These new product offerings range from various sizes of fresh-cut bagged products, to vegetable trays, to whole produce, to vegetable salads and snack packs. During the last twelve months, Apio has introduced 15 new products.

Apio established its Apio Packaging division (formerly know as Apio Tech) in 2005 to advance the sales of BreatheWay packaging technology for shelf-life sensitive vegetables and fruit. The technology also includes unique packaging solutions for produce in large packages including shipping and pallet-sized containers.

Apio Packaging's first program has been concentrated on bananas which was formally consummated when Apio entered into an agreement with Chiquita Brands International, Inc. ("Chiquita") whereby Apio supplies Chiquita with its proprietary banana packaging technology on a worldwide basis for the ripening, conservation and shelf-life extension of bananas in selective applications on an exclusive basis and for other applications on a non-exclusive basis. In addition, Apio provides Chiquita with ongoing research and development and process technology support for the BreatheWay membranes and bags, and technical service support throughout the customer chain in order to assist in the development and market acceptance of the technology. To maintain the exclusive license, Chiquita must meet annual minimum purchase thresholds of BreatheWay banana packages.

The initial market focus for the BreatheWay banana packaging technology using Chiquita® Brand bananas has been commercial outlets that normally do not sell bananas because of their short shelf-life - outlets such as quick serve restaurants, convenience stores and coffee chain outlets. Chiquita is currently market testing the sale of bananas packaged with Landec's BreatheWay technology to retail grocery chains.

The Company recently expanded the use of its BreatheWay technology to avocados under an expanded licensing agreement with Chiquita. Market test are expected to start within the next twelve months.

Technology Licensing Businesses

The Technology and Market Opportunity: Intellicoat Seed Coatings

Following the sale of FCD, our strategy is to work closely with Monsanto to further develop our patented, functional polymer coating technology that can be broadly sold and/or licensed to the seed industry. In accordance with our license, supply and R&D agreement with Monsanto, we are currently focused on commercializing products for the seed corn market and then plan to broaden the technology to other seed crop applications.

Landec's Intellicoat seed coating applications are designed to control seed germination timing, increase crop yields, reduce risks and extend cropplanting windows. These coatings are currently available on hybrid corn, soybeans and male inbred corn used for seed production. In fiscal year 2000, Landec Ag launched its first commercial product, Pollinator Plusâ coatings, which is a coating application used by seed companies as a method for spreading pollination to increase yields and reduce risk in the production of hybrid seed corn. There are approximately 650,000 acres of seed production in the United States and in 2007 Pollinator Plus was used by 25 seed companies on approximately 15% of the seed corn production acres in the U.S.

In 2003, Landec commercialized Early Plantâ corn by selling the product directly to farmers through the Fielder's Choice Directâ brand. This application allows farmers to plant into cold soils without the risk of chilling injury, and enables farmers to plant as much as four weeks earlier than normal. With this capability, farmers are able to utilize labor and equipment more efficiently, provide flexibility during the critical planting period and avoid yield losses caused by late planting. In 2007, seven seed companies offered Intellicoat on their hybrid seed corn offerings.

The Technology and Market Opportunity: Intelimer Polymer Applications

We believe our technology has commercial potential in a wide range of industrial, consumer and medical applications. For example, our core patented technology, Intelimer materials, can be used to trigger the release of small molecule drugs, catalysts, pesticides or fragrances just by changing the temperature of the Intelimer materials or to activate adhesives through controlled temperature change. In order to exploit these opportunities, we have entered into and will enter into licensing and collaborative agreements for product development and/or distribution in certain fields. However, given the infrequency and unpredictability of when the Company may enter into any such licensing and research and development arrangements, the Company is unable to disclose its financial expectations in advance of entering into such arrangements.

Personal Care and Cosmetic Applications

Lander's personal care and cosmetic applications strategy is focused on supplying Intelimer materials to industry leaders for use in lotions and creams, and potentially hair care products, color cosmetics and lipsticks. The Company's partner, Air Products, is currently shipping products to L'Oreal for use in lotions and creams.

Intelimer Polymer Systems

Landec has developed latent catalysts useful in extending pot-life, extending shelf life, reducing waste and improving thermoset cure methods. Some of these latent catalysts are currently being distributed by Akzo-Nobel Chemicals B.V. through our licensing agreement with Air Products. The rights to develop and sell Landec's latent catalysts and personal care technologies were licensed to Air Products in March 2006.

Medical Applications

On December 23, 2005, Landec entered into an exclusive licensing agreement with Aesthetic Sciences Corporation ("Aesthetic Sciences") for the exclusive rights to use Landec's Intelimer materials technology for the development of dermal fillers worldwide. Landec will receive royalties on the sale of products incorporating Landec's technology. In addition, the Company has received shares of preferred stock valued at \$1.8 million which represents a 19.9% ownership interest in Aesthetic Sciences. At this time, the Company is unable to predict the ultimate outcome of the collaboration with Aesthetic Sciences and the timing or amount of future revenues, if any.

Results of Operations

Revenues (in thousands):

	Three months ended 8/26/07		Three months ended 8/27/06		Change
Apio Value Added	\$	39,394	\$	35,030	12%
Apio Packaging		153		13	1077%
Apio Tech. Subtotal		39,547		35,043	13%
Apio Trading		21,451		15,782	36%
Total Apio		60,998		50,825	20%
Tech. Licensing		1,661		322	416%
Total Revenues	\$	62,659	\$	51,147	23%

Apio Value Added

Apio's value-added revenues consist of revenues generated from the sale of specialty packaged fresh-cut and whole value-added processed vegetable products that are washed and packaged in our proprietary packaging and sold under Apio's Eat Smart brand and various private labels. In addition, value-added revenues include the revenues generated from Apio Cooling, LP, a vegetable cooling operation in which Apio is the general partner with a 60% ownership position.

The increase in Apio's value-added revenues for the three months ended August 26, 2007 compared to the same period last year is due to increased sales to existing customers and the addition of new customers. Overall value-added sales volume increased 20% during the first quarter of fiscal year 2008 compared to the same period last year. The increase in value-added sales volumes was higher than the increase in revenues due primarily to the introduction of several new value-added products that have average sales prices that are lower than the average sales prices for other value-added products.

Apio Packaging

Apio Packaging consists of Apio's packaging technology business using its BreatheWay membrane technology. The first commercial application included in Apio Packaging is our banana packaging technology. A large majority of the revenues currently generated from Apio Packaging are revenues derived from our banana packaging program with Chiquita.

The increase in revenues at Apio Packaging during the three months ended August 26, 2007 compared to the same period last year was not material to consolidated Landec revenues.

Apio Trading

Apio trading revenues consist of revenues generated from the purchase and sale of primarily whole commodity fruit and vegetable products to Asia through Apio's export company, Cal-Ex and from the purchase and sale of whole commodity fruit and vegetable products domestically to Wal-Mart. The export portion of trading revenues for the first quarter of fiscal year 2008 was \$19.3 million or 90% of total trading revenues.

The increase in revenues in Apio's trading business for the three months ended August 26, 2007 compared to the same period last year was due to a 40% increase in export sales volumes as a result of an increased supply of produce to export.

Technology Licensing

Technology licensing revenues consist of revenues generated from the licensing agreements with Monsanto, Air Products and Nitta.

The increase in Technology Licensing revenues for the three months ended August 26, 2007 compared to the same period of the prior year was primarily due to the licensing revenues from the Monsanto licensing agreement entered into on December 1, 2006.

Gross Profit (in thousands):

	 Three months ended 8/26/07 ended 8/27/06		Change
Apio Value Added	\$ 6,103	\$ 4,523	35%
Apio Packaging	119	4	2875%
Apio Tech. Subtotal	6,222	4,527	37%
Apio Trading	1,091	827	32%
Total Apio	7,313	5,354	37%
Tech. Licensing	 1,661	202	722%
Total Gross Profit	\$ 8,974	\$ 5,556	62%

General

There are numerous factors that can influence gross profit including product mix, customer mix, manufacturing costs, volume, sale discounts and charges for excess or obsolete inventory, to name a few. Many of these factors influence or are interrelated with other factors. Therefore, it is difficult to precisely quantify the impact of each item individually. The Company includes in cost of sales all the costs related to the sale of products in accordance with generally accepted accounting principles. These costs include the following: raw materials (including produce and packaging), direct labor, overhead (including indirect labor, depreciation, and facility related costs) and shipping and shipping related costs. The following discussion surrounding gross profit includes management's best estimates of the reasons for the changes for the first quarter of fiscal year 2008 compared to the same period last year as outlined in the table above.

Apio Value-Added

The increase in gross profit for Apio's value-added specialty packaged vegetable business for the three months ended August 26, 2007 compared to the same period last year was primarily due to the decreased costs for raw materials in the first quarter of fiscal year 2008 compared to the first quarter of last year. Increased raw material costs in prior periods were primarily attributable to weather related shortages of contracted product during the first quarter of fiscal year 2007 which required Apio to procure supplemental product on the open market at costs significantly above contracted prices. The increase in gross profits was also due in part to the increase in revenues of 12% during the first quarter of fiscal year 2008 compared to the first quarter of last year.

Apio Packaging

The increase in gross profit for Apio Packaging for the three months ended August 26, 2007 compared to the same period last year was not material to consolidated Landec gross profit.

Apio Trading

Apio's trading business is a buy/sell business that realizes a commission-based margin in the 4-6% range. The increase in gross profit for Apio's trading business during the three months ended August 26, 2007 compared to the same period last year was primarily due to a 36% increase in revenues.

Technology Licensing

The increase in Technology Licensing gross profit for the three months ended August 26, 2007 compared to the same period of the prior year was primarily due to the licensing income from the Monsanto licensing agreement entered into on December 1, 2006.

Operating Expenses (in thousands):

	 Three months ended 8/26/07		ree months led 8/27/06	Change
Research and Development:				
Apio	\$ 370	\$	241	54%
Tech. Licensing	 452		543	(17%)
Total R&D	\$ 822	\$	784	5%
Selling, General and Administrative:				
Apio	\$ 3,361	\$	2,791	20%
Corporate	 1,185		2,111	(44%)
Total S,G&A	\$ 4,546	\$	4,902	(7%)

Research and Development

Lander's research and development expenses consist primarily of expenses involved in the development and process scale-up initiatives. Research and development efforts at Apio are focused on the Company's proprietary BreatheWay membranes used for packaging produce, with recent focus on extending the shelf life of bananas and other shelf-life sensitive vegetables and fruit. In the Technology Licensing business, the research and development efforts are focused on the Company's proprietary Intellicoat coatings for seeds, primarily corn seed and on uses for our proprietary Intellimer polymers outside of food and agriculture.

The increase in research and development expenses for the three months ended August 26, 2007 compared to the same period last year was not material.

Selling, General and Administrative

Selling, general and administrative expenses consist primarily of sales and marketing expenses associated with Landec's product sales and services, business development expenses and staff and administrative expenses.

The decrease in selling, general and administrative expenses for the three months ended August 26, 2007 compared to the same period last year was primarily due to the fact that included in selling, general and administrative expenses for Corporate in the first quarter of fiscal year 2007 was \$2.3 million in expenses from Landec's former direct marketing and sales seed business which was sold to Monsanto in December 2006. These seed related expenses in the first quarter of fiscal year 2007 were partially offset by the recording of net proceeds of \$1.3 million from an insurance settlement. This decrease was partially offset by an increase in selling and marketing expenses at Apio during the first quarter of fiscal year 2008 compared to the same period last year.

Other (in thousands):

	 Three months ended 8/26/07		ee months ed 8/27/06	Change	
Interest Income	\$ 781	\$	236	231%	
Interest Expense	(8)		(70)	(89%)	
Minority Interest Exp.	(120)		(18)	567%	
Other Expense	_		(4)	N/M	
	\$ 653	\$	144	353%	
Income Taxes	\$ 1,182	\$	_	N/M	

Interest Income

The increase in interest income for the three months ended August 26, 2007 compared to the same period last year was primarily due to the increase in cash available for investing.

Interest Expense

The decrease in interest expense during the three months ended August 26, 2007 compared to the same period last year was due to the Company's reduction of debt.

Minority Interest Expense

The minority interest expense consists of the minority interest associated with the limited partners' equity interest in the net income of Apio Cooling, LP.

The increase in the minority interest for the three months ended August 26, 2007 compared to the first quarter of last year was not material to consolidated Landec net income.

Other

Other consists of non-operating income and expenses.

Income Taxes

The increase in the income tax expense is due to the Company utilizing all of its net operating loss carryforwards and tax credits during fiscal year 2008 for income tax expense purposes which resulted in an estimated effective tax rate for fiscal year 2008 of approximately 28% and therefore the Company recording a tax provision of \$1.2 million during the first quarter of fiscal year 2008 for federal and state income taxes.

Liquidity and Capital Resources

As of August 26, 2007, the Company had cash and cash equivalents of \$46.3 million, a net decrease of \$16.3 million from \$62.6 million at May 27, 2007.

Cash Flow from Operating Activities

Landec generated \$4.2 million of cash flow from operating activities during the three months ended August 26, 2007 compared to using \$1.9 million in operating activities for the three months ended August 27, 2006. The primary sources of cash from operating activities were from generating \$3.1 million of net income and from non-cash related expenses of \$2.3 million, such as depreciation, income tax expenses not payable and stock based compensation. The sources of cash were partially offset by a decrease in current assets net of current liabilities of \$1.2 million. The primary components of this decrease in current assets net of current liabilities was an increase in inventories and correspondingly an increase in accounts payables at Apio due to an increase in operating activities, a decrease in accrued compensation as a result of bonus payments earned in fiscal year 2007 and a decrease in deferred revenue from recognizing revenues associated with the Monsanto purchase of FCD and the Intellicoat license agreement with Monsanto (see Note 2).

Cash Flow from Investing Activities

Net cash used in investing activities for the three months ended August 26, 2007 was \$240,000 compared to \$2.3 million for the same period last year. The primary uses of cash from investing activities during the first quarter of fiscal year 2008 were for the purchase of \$236,000 of property and equipment primarily for the further automation of Apio's value-added facility.

Cash Flow from Financing Activities

Net cash used in financing activities for the three months ended August 26, 2007 was \$20.2 million compared to \$1.9 million for the same period last year. The primary uses of cash from financing activities during the first quarter of fiscal year 2008 were for the repurchase of all of the outstanding common stock and options of Apio not owned by Landec for \$20.6 million (see Note 6).

Capital Expenditures

During the three months ended August 26, 2007, Landec purchased vegetable processing equipment to support the further automation of Apio's value added processing facility. These expenditures represented the majority of the \$236,000 of capital expenditures.

Debt

Apio has a \$7.0 million revolving line of credit with Wells Fargo Bank N.A. outstanding amounts under the line of credit bear interest at either the prime rate less 0.25% or the LIBOR adjustable rate plus 1.75%. The revolving line of credit with Wells Fargo (collectively, the "Loan Agreement") contains certain restrictive covenants, which require Apio to meet certain financial tests, including minimum levels of net income, maximum leverage ratio, minimum net worth and maximum capital expenditures. Landec has pledged substantially all of the assets of Apio to secure the lines with Wells Fargo. At August 26, 2007, no amounts were outstanding under the revolving line of credit. Apio has been in compliance or received waivers for all loan covenants since the inception of this loan.

On September 1, 2007, Apio amended its revolving line of credit with Wells Fargo Bank N.A. extending the term of the line to August 31, 2009. In addition, the interest rate on the revolving line of credit was reduced to either prime less 0.50% or the LIBOR adjusted rate plus 1.50%.

Landec is not a party to any agreements with, or commitments to, any special purpose entities that would constitute material off-balance sheet financing other than the operating lease commitments listed above.

Landec's future capital requirements will depend on numerous factors, including the progress of its research and development programs; the continued development of marketing, sales and distribution capabilities; the ability of Landec to establish and maintain new collaborative and licensing arrangements; any decision to pursue additional acquisition opportunities; weather conditions that can affect the supply and price of produce, the timing and amount, if any, of payments received under licensing and research and development agreements; the costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; the ability to comply with regulatory requirements; the emergence of competitive technology and market forces; the effectiveness of product commercialization activities and arrangements; and other factors. If Landec's currently available funds, together with the internally generated cash flow from operations are not sufficient to satisfy its capital needs, Landec would be required to seek additional funding through other arrangements with collaborative partners, additional bank borrowings and public or private sales of its securities. There can be no assurance that additional funds, if required, will be available to Landec on favorable terms if at all.

Landec believes that its debt facilities, cash from operations, along with existing cash, cash equivalents and existing borrowing capacities will be sufficient to finance its operational and capital requirements for the foreseeable future.

Additional Factors That May Affect Future Results

Landec desires to take advantage of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995 and of Section 21E and Rule 3b-6 under the Securities Exchange Act of 1934. Specifically, Landec wishes to alert readers that the following important factors, as well as other factors including, without limitation, those described elsewhere in this report, could in the future affect, and in the past have affected, Landec's actual results and could cause Landec's results for future periods to differ materially from those expressed in any forward-looking statements made by or on behalf of Landec. Landec assumes no obligation to update such forward-looking statements.

Our Future Operating Results Are Likely to Fluctuate Which May Cause Our Stock Price to Decline

In the past, our results of operations have fluctuated significantly from quarter to quarter and are expected to continue to fluctuate in the future. Historically, Landec Ag has been the primary source of these fluctuations, as its revenues and profits were concentrated over a few months during the spring planting season (generally during our third and fourth fiscal quarters). In addition, Apio can be heavily affected by seasonal and weather factors which have impacted quarterly results, such as the high cost of sourcing product in June/July 2006 and January 2007 due to a shortage of essential value-added produce items. Our earnings may also fluctuate based on our ability to collect accounts receivables from customers and note receivables from growers and on price fluctuations in the fresh vegetables and fruits markets. Other factors that affect our food and/or agricultural operations include:

- · the seasonality of our supplies;
- · our ability to process produce during critical harvest periods;
- the timing and effects of ripening;
- the degree of perishability;
- · the effectiveness of worldwide distribution systems;
- total worldwide industry volumes;
- the seasonality of consumer demand;
- · foreign currency fluctuations; and
- · foreign importation restrictions and foreign political risks.

As a result of these and other factors, we expect to continue to experience fluctuations in quarterly operating results.

We May Not Be Able to Achieve Acceptance of Our New Products in the Marketplace

Our success in generating significant sales of our products will depend in part on the ability of us and our partners and licensees to achieve market acceptance of our new products and technology. The extent to which, and rate at which, we achieve market acceptance and penetration of our current and future products is a function of many variables including, but not limited to:

- · price;
- · safety;
- efficacy;
- · reliability;
- · conversion costs;
- · marketing and sales efforts; and
- · general economic conditions affecting purchasing patterns.

We may not be able to develop and introduce new products and technologies in a timely manner or new products and technologies may not gain market acceptance. We are in the early stage of product commercialization of certain Intelimer-based specialty packaging, Intellicoat seed coatings and other Intelimer polymer products and many of our potential products are in development. We believe that our future growth will depend in large part on our ability to develop and market new products in our target markets and in new markets. In particular, we expect that our ability to compete effectively with existing food products, agricultural, industrial and medical companies will depend substantially on successfully developing, commercializing, achieving market acceptance of and reducing the cost of producing our products. In addition, commercial applications of our temperature switch polymer technology are relatively new and evolving. Our failure to develop new products or the failure of our new products to achieve market acceptance would have a material adverse effect on our business, results of operations and financial condition.

We Face Strong Competition in the Marketplace

Competitors may succeed in developing alternative technologies and products that are more effective, easier to use or less expensive than those which have been or are being developed by us or that would render our technology and products obsolete and non-competitive. We operate in highly competitive and rapidly evolving fields, and new developments are expected to continue at a rapid pace. Competition from large food products, agricultural, industrial and medical companies is expected to be intense. In addition, the nature of our collaborative arrangements may result in our corporate partners and licensees becoming our competitors. Many of these competitors have substantially greater financial and technical resources and production and marketing capabilities than we do, and may have substantially greater experience in conducting clinical and field trials, obtaining regulatory approvals and manufacturing and marketing commercial products.

We Have a Concentration of Manufacturing in One Location for Apio and May Have to Depend on Third Parties to Manufacture Our Products

Any disruptions in our primary manufacturing operation at Apio's facility in Guadalupe, California would reduce our ability to sell our products and would have a material adverse effect on our financial results. Additionally, we may need to consider seeking collaborative arrangements with other companies to manufacture our products. If we become dependent upon third parties for the manufacture of our products, our profit margins and our ability to develop and deliver those products on a timely basis may be affected. Failures by third parties may impair our ability to deliver products on a timely basis and impair our competitive position. We may not be able to continue to successfully operate our manufacturing operations at acceptable costs, with acceptable yields, and retain adequately trained personnel.

Our Dependence on Single-Source Suppliers and Service Providers May Cause Disruption in Our Operations Should Any Supplier Fail to Deliver Materials

We may experience difficulty acquiring materials or services for the manufacture of our products or we may not be able to obtain substitute vendors. We may not be able to procure comparable materials at similar prices and terms within a reasonable time. Several services that are provided to Apio are obtained from a single provider. Several of the raw materials we use to manufacture our products are currently purchased from a single source, including some monomers used to synthesize Intelimer polymers and substrate materials for our breathable membrane products. Any interruption of our relationship with single-source suppliers or service providers could delay product shipments and materially harm our business.

We May Be Unable to Adequately Protect Our Intellectual Property Rights

We may receive notices from third parties, including some of our competitors, claiming infringement by our products of patent and other proprietary rights. Regardless of their merit, responding to any such claim could be time-consuming, result in costly litigation and require us to enter royalty and licensing agreements which may not be offered or available on terms acceptable to us. If a successful claim is made against us and we fail to develop or license a substitute technology, we could be required to alter our products or processes and our business, results of operations or financial position could be materially adversely affected. Our success depends in large part on our ability to obtain patents, maintain trade secret protection and operate without infringing on the proprietary rights of third parties. Any pending patent applications we file may not be approved and we may not be able to develop additional proprietary products that are patentable. Any patents issued to us may not provide us with competitive advantages or may be challenged by third parties. Patents held by others may prevent the commercialization of products incorporating our technology. Furthermore, others may independently develop similar products, duplicate our products or design around our patents.

Our Operations Are Subject to Regulations that Directly Impact Our Business

Our food packaging products are subject to regulation under the Food, Drug and Cosmetic Act (the "FDC Act"). Under the FDC Act, any substance that when used as intended may reasonably be expected to become, directly or indirectly, a component or otherwise affect the characteristics of any food may be regulated as a food additive unless the substance is generally recognized as safe. We believe that food packaging materials are generally not considered food additives by the FDA because these products are not expected to become components of food under their expected conditions of use. We consider our breathable membrane product to be a food packaging material not subject to regulation or approval by the FDA. We have not received any communication from the FDA concerning our breathable membrane product. If the FDA were to determine that our breathable membrane products are food additives, we may be required to submit a food additive petition for approval by the FDA. The food additive petition process is lengthy, expensive and uncertain. A determination by the FDA that a food additive petition is necessary would have a material adverse effect on our business, operating results and financial condition.

Federal, state and local regulations impose various environmental controls on the use, storage, discharge or disposal of toxic, volatile or otherwise hazardous chemicals and gases used in some of the manufacturing processes. Our failure to control the use of, or to restrict adequately the discharge of, hazardous substances under present or future regulations could subject us to substantial liability or could cause our manufacturing operations to be suspended and changes in environmental regulations may impose the need for additional capital equipment or other requirements.

Our agricultural operations are subject to a variety of environmental laws including, the Food Quality Protection Act of 1966, the Clean Air Act, the Clean Water Act, the Resource Conservation and Recovery Act, the Federal Insecticide, Fungicide and Rodenticide Act, and the Comprehensive Environmental Response, Compensation and Liability Act. Compliance with these laws and related regulations is an ongoing process. Environmental concerns are, however, inherent in most agricultural operations, including those we conduct. Moreover, it is possible that future developments, such as increasingly strict environmental laws and enforcement policies could result in increased compliance costs.

The Company is subject to the Perishable Agricultural Commodities Act ("PACA") law. PACA regulates fair trade standards in the fresh produce industry and governs all the products sold by Apio. Our failure to comply with the PACA requirements could among other things, result in civil penalties, suspension or revocation of a license to sell produce, and in the most egregious cases, criminal prosecution, which could have a material adverse effect on our business.

Adverse Weather Conditions and Other Acts of God May Cause Substantial Decreases in Our Sales and/or Increases in Our Costs

Our Food Products business is subject to weather conditions that affect commodity prices, crop yields, and decisions by growers regarding crops to be planted. Crop diseases and severe conditions, particularly weather conditions such as floods, droughts, frosts, windstorms, earthquakes and hurricanes, may adversely affect the supply of vegetables and fruits used in our business, which could reduce the sales volumes and/or increase the unit production costs. Because a significant portion of the costs are fixed and contracted in advance of each operating year, volume declines due to production interruptions or other factors could result in increases in unit production costs which could result in substantial losses and weaken our financial condition.

We Depend on Strategic Partners and Licenses for Future Development

Our strategy for development, clinical and field testing, manufacture, commercialization and marketing for some of our current and future products includes entering into various collaborations with corporate partners, licensees and others. We are dependent on our corporate partners to develop, test, manufacture and/or market some of our products. Although we believe that our partners in these collaborations have an economic motivation to succeed in performing their contractual responsibilities, the amount and timing of resources to be devoted to these activities are not within our control. Our partners may not perform their obligations as expected or we may not derive any additional revenue from the arrangements. Our partners may not pay any additional option or license fees to us or may not develop, market or pay any royalty fees related to products under the agreements. Moreover, some of the collaborative agreements provide that they may be terminated at the discretion of the corporate partner, and some of the collaborative agreements provide for termination under other circumstances. Our partners may pursue existing or alternative technologies in preference to our technology. Furthermore, we may not be able to negotiate additional collaborative arrangements in the future on acceptable terms, if at all, and our collaborative arrangements may not be successful.

Both Domestic and Foreign Government Regulations Can Have an Adverse Effect on Our Business Operations

Our products and operations are subject to governmental regulation in the United States and foreign countries. The manufacture of our products is subject to periodic inspection by regulatory authorities. We may not be able to obtain necessary regulatory approvals on a timely basis or at all. Delays in receipt of or failure to receive approvals or loss of previously received approvals would have a material adverse effect on our business, financial condition and results of operations. Although we have no reason to believe that we will not be able to comply with all applicable regulations regarding the manufacture and sale of our products and polymer materials, regulations are always subject to change and depend heavily on administrative interpretations and the country in which the products are sold. Future changes in regulations or interpretations relating to matters such as safe working conditions, laboratory and manufacturing practices, environmental controls, and disposal of hazardous or potentially hazardous substances may adversely affect our business.

We are subject to USDA rules and regulations concerning the safety of the food products handled and sold by Apio, and the facilities in which they are packed and processed. Failure to comply with the applicable regulatory requirements can, among other things, result in:

- · fines, injunctions, civil penalties, and suspensions,
- · withdrawal of regulatory approvals,
- · product recalls and product seizures, including cessation of manufacturing and sales,
- · operating restrictions, and
- · criminal prosecution.

We may be required to incur significant costs to comply with the laws and regulations in the future which may have a material adverse effect on our business, operating results and financial condition.

Our International Operations and Sales May Expose Our Business to Additional Risks

For the three months ended August 26, 2007, approximately 31% of our total revenues were derived from product sales to international customers. A number of risks are inherent in international transactions. International sales and operations may be limited or disrupted by any of the following:

- · regulatory approval process,
- · government controls,
- · export license requirements,
- · political instability,
- · price controls,
- · trade restrictions,
- · changes in tariffs, or
- · difficulties in staffing and managing international operations.

Foreign regulatory agencies have or may establish product standards different from those in the United States, and any inability to obtain foreign regulatory approvals on a timely basis could have a material adverse effect on our international business, and our financial condition and results of operations. While our foreign sales are currently priced in dollars, fluctuations in currency exchange rates may reduce the demand for our products by increasing the price of our products in the currency of the countries to which the products are sold. Regulatory, geopolitical and other factors may adversely impact our operations in the future or require us to modify our current business practices.

Cancellations or Delays of Orders by Our Customers May Adversely Affect Our Business

During the three months ended August 26, 2007, sales to our top five customers accounted for approximately 49% of our revenues, with our largest customer, Costco Wholesale Corp. accounting for approximately 20% of our revenues. We expect that, for the foreseeable future, a limited number of customers may continue to account for a substantial portion of our net revenues. We may experience changes in the composition of our customer base as we have experienced in the past. We do not have long-term purchase agreements with any of our customers. The reduction, delay or cancellation of orders from one or more major customers for any reason or the loss of one or more of our major customers could materially and adversely affect our business, operating results and financial condition. In addition, since some of the products processed by Apio at its Guadalupe, California facility are sole sourced to its customers, our operating results could be adversely affected if one or more of our major customers were to develop other sources of supply. Our current customers may not continue to place orders, orders by existing customers may be canceled or may not continue at the levels of previous periods or we may not be able to obtain orders from new customers.

Our Sale of Some Products May Increase Our Exposure to Product Liability Claims

The testing, manufacturing, marketing, and sale of the products we develop involve an inherent risk of allegations of product liability. If any of our products were determined or alleged to be contaminated or defective or to have caused a harmful accident to an end-customer, we could incur substantial costs in responding to complaints or litigation regarding our products and our product brand image could be materially damaged. Either event may have a material adverse effect on our business, operating results and financial condition. Although we have taken and intend to continue to take what we believe are appropriate precautions to minimize exposure to product liability claims, we may not be able to avoid significant liability. We currently maintain product liability insurance. While we believe the coverage and limits are consistent with industry standards, our coverage may not be adequate or may not continue to be available at an acceptable cost, if at all. A product liability claim, product recall or other claim with respect to uninsured liabilities or in excess of insured liabilities could have a material adverse effect on our business, operating results and financial condition.

Our Stock Price May Fluctuate in Accordance with Market Conditions

The following events may cause the market price of our common stock to fluctuate significantly:

- · technological innovations applicable to our products,
- · our attainment of (or failure to attain) milestones in the commercialization of our technology,
- · our development of new products or the development of new products by our competitors,
- · new patents or changes in existing patents applicable to our products,
- · our acquisition of new businesses or the sale or disposal of a part of our businesses,
- · development of new collaborative arrangements by us, our competitors or other parties,
- · changes in government regulations applicable to our business,
- · changes in investor perception of our business,
- · fluctuations in our operating results and
- · changes in the general market conditions in our industry.

These broad fluctuations may adversely affect the market price of our common stock.

Our Controlling Shareholders Exert Significant Influence over Corporate Events that May Conflict with the Interests of Other Shareholders

Our executive officers and directors and their affiliates own or control approximately 17% of our common stock (including options exercisable within 60 days). Accordingly, these officers, directors and shareholders may have the ability to exert significant influence over the election of our Board of Directors, the approval of amendments to our articles and bylaws and the approval of mergers or other business combination transactions requiring shareholder approval. This concentration of ownership may have the effect of delaying or preventing a merger or other business combination transaction, even if the transaction or amendments would be beneficial to our other shareholders. In addition, our controlling shareholders may approve amendments to our articles or bylaws to implement anti-takeover or management friendly provisions that may not be beneficial to our other shareholders.

We May Be Exposed to Employment Related Claims and Costs that Could Materially Adversely Affect Our Business

We have been subject in the past, and may be in the future, to claims by employees based on allegations of discrimination, negligence, harassment and inadvertent employment of illegal aliens or unlicensed personnel, and we may be subject to payment of workers' compensation claims and other similar claims. We could incur substantial costs and our management could spend a significant amount of time responding to such complaints or litigation regarding employee claims, which may have a material adverse effect on our business, operating results and financial condition.

We Are Dependent on Our Key Employees and if One or More of Them Were to Leave, We Could Experience Difficulties in Replacing Them and Our Operating Results Could Suffer

The success of our business depends to a significant extent upon the continued service and performance of a relatively small number of key senior management, technical, sales, and marketing personnel. The loss of any of our key personnel would likely harm our business. In addition, competition for senior level personnel with knowledge and experience in our different lines of business is intense. If any of our key personnel were to leave, we would need to devote substantial resources and management attention to replace them. As a result, management attention may be diverted from managing our business, and we may need to pay higher compensation to replace these employees.

We May Issue Preferred Stock with Preferential Rights that Could Affect Your Rights

Our Board of Directors has the authority, without further approval of our shareholders, to fix the rights and preferences, and to issue shares, of preferred stock. In November 1999, we issued and sold shares of Series A Convertible Preferred Stock and in October 2001 we issued and sold shares of Series B Convertible Preferred Stock. The Series A Convertible Preferred Stock was converted into 1,666,670 shares of Common Stock on November 19, 2002 and the Series B Convertible Preferred Stock was converted into 1,744,102 shares of Common Stock on May 7, 2004.

The issuance of new shares of preferred stock could have the effect of making it more difficult for a third party to acquire a majority of our outstanding stock, and the holders of such preferred stock could have voting, dividend, liquidation and other rights superior to those of holders of our Common Stock.

We Have Never Paid any Dividends on Our Common Stock

We have not paid any cash dividends on our Common Stock since inception and do not expect to do so in the foreseeable future. Any dividends may be subject to preferential dividends payable on any preferred stock we may issue.

Our Profitability Could Be Materially and Adversely Affected if it Is Determined that the Book Value of Goodwill is Higher than Fair Value

Our balance sheet includes an amount designated as "goodwill" that represents a portion of our assets and our shareholders' equity. Goodwill arises when an acquirer pays more for a business than the fair value of the tangible and separately measurable intangible net assets. Under Statement of Financial Accounting Standards No. 142 "Goodwill and Other Intangible Assets", beginning in fiscal year 2002, the amortization of goodwill has been replaced with an "impairment test" which requires that we compare the fair value of goodwill to its book value at least annually and more frequently if circumstances indicate a possible impairment. If we determine at any time in the future that the book value of goodwill is higher than fair value then the difference must be written-off, which could materially and adversely affect our profitability.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

None.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management evaluated, with participation of our Chief Executive Officer and our Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective in ensuring that information required to be disclosed in reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission, and to provide reasonable assurance that information required to be disclosed by the Company in such reports is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal controls over financial reporting during the quarter ended August 26, 2007 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

The Company is involved in litigation arising in the normal course of business. The Company is currently not a party to any legal proceedings which management believes could result in the payment of any amounts that would be material to the business or financial condition of the Company.

Item 1A. Risk Factors

Not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults Upon Senior Securities

None.

Item 4. Submission of Matters to a Vote of Security Holders

None.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit

Number Exhibit Title:

31.1+ CEO Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.

31.2+ CFO Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.

32.1+ CEO Certification pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

32.2+ CFO Certification pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

-30-

⁺ Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

LANDEC CORPORATION

By:	/s/ Gregory S. Skinner
	Gregory S. Skinner
	Vice President, Finance and Chief Financial Officer
	(Principal Financial and Accounting Officer)

-31-

Date: September 28, 2007

CERTIFICATION

I, Gary T. Steele, certify that:

- I have reviewed this quarterly report on Form 10-Q of Landec Corporation;
- 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
- (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
- (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- (c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation, and
- (d) disclosed in this quarterly report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: September 28, 2007

/s/ Gary T. Steele
Gary T. Steele
Chief Executive Officer

CERTIFICATION

I, Gregory S. Skinner, certify that:

- I have reviewed this quarterly report on Form 10-Q of Landec Corporation;
- 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
- (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
- (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- (c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and
- (d) disclosed in this quarterly report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: September 28, 2007
/s/ Gregory S. Skinner
Gregory S. Skinner
Chief Financial Officer

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Landec Corporation (the "Company") on Form 10-Q for the period ending August 26, 2007 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Gary T. Steele, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: September 28, 2007

/s/ Gary T. Steele
Gary T. Steele
Chief Executive Officer and President
(Principal Executive Officer)

* The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Landec Corporation (the "Company") on Form 10-Q for the period ending August 26, 2007 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Gregory S. Skinner, Vice President of Finance and Administration and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: September 28, 2007

/s/ Gregory S. Skinner
Gregory S. Skinner
Vice President and Chief Financial Officer
(Principal Accounting Officer)

* The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.